Background: Matrix metalloproteinases (MMP) are being considered important mediators in cancer invasion, and plenty of research is in progress. Our objective was to evaluate the presence of MMP-2 and tissue inhibitor of metalloproteinase (TIMP-2) in oral lichen planus (OLP) and to assess its role in the pathogenesis of OLP and as an indicator of malignant transformation.
Materials and methods: Immunohistochemical analysis for MMP-2 and TIMP-2 was performed in thirty histopathologically confirmed, formalin-fixed, paraffin-embedded specimens of OLP (24 cases of reticular and 6 cases of erosive LP). A semi-quantitative analysis was done to assess the expression and distribution of this marker in these lesions.
Results: In all cases of OLP, MMP-2 expression was seen mainly in areas of lymphocytic inflammatory infiltrate (100%) in the lamina propria within the overlying epithelium. TIMP-2 expression was seen more than 50% in the fibroblasts and basal and parabasal cells.
Conclusion: The expression of MMP-2 and TIMP-2 was observed in all cases of OLP. However, a clinical 5-year follow-up of the lesion revealed no progression of the disease except for chronic exacerbation and regression of these lesions. Although our study considers MMP-2 and TIMP-2 as mediators in the pathogenesis of OLP, it still remains debatable whether they have a direct role to play in the disease process or whether they are suitable biomarkers to assess the disease progression.
Keywords: Biomarkers; excision; inflammation; lichen planus; malignancy.
Copyright: © 2019 Journal of Oral and Maxillofacial Pathology.
Conflict of interest statement
There are no conflicts of interest.
Evaluation of matrix metalloproteinases-2 (MMP-2) and tissue inhibitors of metalloproteinases-2 (TIMP-2) in oral submucous fibrosis and their correlation with disease severity.Kathmandu Univ Med J (KUMJ). 2013 Oct-Dec;11(44):274-81. doi: 10.3126/kumj.v11i4.12521. Kathmandu Univ Med J (KUMJ). 2013. PMID: 24899319
Matrix metalloproteinases and their inhibitors in oral lichen planus.J Cutan Pathol. 2001 Feb;28(2):72-82. doi: 10.1034/j.1600-0560.2001.280203.x. J Cutan Pathol. 2001. PMID: 11168755
MMP-1, MMP-9, and TIMP-1 levels in oral lichen planus patients with gingivitis or periodontitis.Arch Oral Biol. 2013 Jul;58(7):843-52. doi: 10.1016/j.archoralbio.2013.01.015. Epub 2013 Feb 21. Arch Oral Biol. 2013. PMID: 23433942
Evaluation of Potential Risk Factors that contribute to Malignant Transformation of Oral Lichen Planus: A Literature Review.J Contemp Dent Pract. 2016 Aug 1;17(8):692-701. doi: 10.5005/jp-journals-10024-1914. J Contemp Dent Pract. 2016. PMID: 27659090 Review.
The pathogenesis of oral lichen planus.Crit Rev Oral Biol Med. 2002;13(4):350-65. doi: 10.1177/154411130201300405. Crit Rev Oral Biol Med. 2002. PMID: 12191961 Review.
- Dissemond J. Oral lichen planus: An overview. J Dermatolog Treat. 2004;15:136–40. - PubMed
- Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: A study of 723 patients. J Am Acad Dermatol. 2002;46:207–14. - PubMed
- van der Waal I. Oral lichen planus and oral lichenoid lesions; a critical appraisal with emphasis on the diagnostic aspects. Med Oral Patol Oral Cir Bucal. 2009;14:E310–4. - PubMed
- Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: Etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci. 2007;49:89–106. - PubMed